<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01325558</url>
  </required_header>
  <id_info>
    <org_study_id>CA-ALT-836-02-10</org_study_id>
    <nct_id>NCT01325558</nct_id>
  </id_info>
  <brief_title>A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase I, Open-Label, Multi-center, Competitive Enrollment and Dose-escalation Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altor BioScience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Altor BioScience</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, open-label, multi-center, competitive enrollment and dose-escalation study&#xD;
      of ALT-836 in combination with standard of care gemcitabine in participants who have locally&#xD;
      advanced or metastatic solid tumors. The purpose of this study is to determine the maximum&#xD;
      tolerated dose (MTD), and to assess the safety and pharmacokinetic profile of ALT-836 given&#xD;
      with gemcitabine. The clinical benefit, progression-free survival and overall survival of&#xD;
      study participants will also be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tissue Factor (TF) is over-expressed in most cancer types. Results from many recent studies&#xD;
      have suggested a key role for TF in the development of cancer-associated thrombosis, tumor&#xD;
      growth, tumor angiogenesis, and tumor metastasis. ALT-836, a recombinant human-chimeric&#xD;
      monoclonal antibody, is designed as a direct TF antagonist to block TF displayed by cancers&#xD;
      and to inhibit cancer-associated venous thromboembolism, tumor growth, tumor angiogenesis and&#xD;
      tumor metastasis. In numerous pre-clinical studies in laboratory animals, including non-human&#xD;
      primates, ALT-836 exhibits potent anti-tumor, anti-thrombotic and anti-inflammatory&#xD;
      activities with a remarkable safety profile. In humans, ALT-836, administered as a single&#xD;
      bolus and monotherapy in patients with coronary artery disease (CAD) and acute lung&#xD;
      injury/acute respiratory distress syndrome (ALI/ARDS), is safe and exhibits anti-coagulant&#xD;
      and anti-inflammatory effects. A Phase II study using a multi-dose regimen of ALT-836 is&#xD;
      being conducted in patients with ALI/ARDS. In the dose-escalation study described in this&#xD;
      protocol, the investigators will assess the safety and determine the maximum tolerated dose&#xD;
      (MTD) of ALT-836 in combination with gemcitabine in patients with advanced malignancies known&#xD;
      to overexpress TF and in which venous thromboembolism is a major complication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of ALT-836 in combination with gemcitabine</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Profile</measure>
    <time_frame>18 months</time_frame>
    <description>Number and severity of treatment related AEs that occur or worsen after the first dose of study treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Benefit</measure>
    <time_frame>18 months</time_frame>
    <description>Number of participants with complete response, partial response or stable disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>36 months</time_frame>
    <description>Number of participants with 9-month, 12-month, 18-month, 24-month, 30-month or 36-month progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>36 months</time_frame>
    <description>Number of participants with 9-month, 12-month, 18-month, 24-month, 30-month or 36-month overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>18 months</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to infinity (AUC) and the half-life of ALT-836</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Locally Advanced Malignant Neoplasm</condition>
  <condition>Malignant Solid Tumour</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALT-836 in combination with gemcitabine</intervention_name>
    <description>Study participants will receive up to four courses of a 28-day biochemotherapy with the study drug (ALT-836) and gemcitabine. Each treatment course consists of five doses of ALT-836 (on Day 1, 4, 8, 15 and 22) and three doses of gemcitabine (Day 1, 8 and 15). Participants with persistent responses will receive additional two cycles, three doses each, of standard of care gemcitabine therapy.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed&#xD;
&#xD;
          -  Locally advanced or metastatic non-hematologic malignancies&#xD;
&#xD;
          -  Measureable&#xD;
&#xD;
          -  Refractory to standard therapies or single agent gemcitabine is indicated as a&#xD;
             standard treatment option&#xD;
&#xD;
        PRIOR/CONCURRENT THERAPY:&#xD;
&#xD;
          -  No concurrent radiotherapy, chemotherapy, immunotherapy or other investigational&#xD;
             agents&#xD;
&#xD;
          -  Must have recovered from side effects of prior therapies&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  &gt; 12 weeks&#xD;
&#xD;
        Performance Status&#xD;
&#xD;
          -  ECOG 0 or 1&#xD;
&#xD;
        Bone Marrow Reserve&#xD;
&#xD;
          -  Absolute Neutrophil count (AGC/ANC) ≥ 1,500/uL&#xD;
&#xD;
          -  Platelets ≥ 100,000/uL&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
        Renal Function&#xD;
&#xD;
          -  Calculated Glomerular filtration rate (GFR) &gt; 59mL/min/1.73M^2&#xD;
&#xD;
        Hepatic Function&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 X ULN&#xD;
&#xD;
          -  AST, ALT, and ALP ≤ 3 X ULN or ≤ 5.0 x ULN, if liver metastasis exists&#xD;
&#xD;
          -  PT INR ≤ 1.5 X ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No history of clinically significant vascular disease&#xD;
&#xD;
          -  No New York Heart Association (NYHA) Class &gt; II heart failure&#xD;
&#xD;
        Hematologic&#xD;
&#xD;
          -  No history of bleeding disorders&#xD;
&#xD;
          -  No evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  No presence of clinically significant hemoptysis or hematuria, presence of serious&#xD;
             non-healing wound or ulceration, or signs of other bleeding&#xD;
&#xD;
          -  No evidence of a tumor invasion of any major blood vessel&#xD;
&#xD;
          -  No trauma with increased risk of life-threatening bleeding or history of severe head&#xD;
             trauma or intracranial surgery within two months of study entry&#xD;
&#xD;
        Surgery/Procedures&#xD;
&#xD;
          -  No major surgery or open biopsy within 28 days before drug infusion or evidence of&#xD;
             active bleeding postoperatively&#xD;
&#xD;
          -  No plan for any major surgery during treatment period&#xD;
&#xD;
          -  No presence or requirement of an epidural catheter or lumbar puncture within 48 hours&#xD;
             prior to each dose of study treatment&#xD;
&#xD;
          -  No anticipation of receiving an epidural catheter or a lumbar puncture within 48 hours&#xD;
             after each dose of study treatment&#xD;
&#xD;
        Excluded Medications or Treatment Regimens&#xD;
&#xD;
          -  Unfractionated heparin of &gt; 15,000 units/day within 8 hours prior to each dose of&#xD;
             study treatment&#xD;
&#xD;
          -  Low-molecular weight heparin at a higher dose than recommended for prophylactic used&#xD;
             or required within 20 hours prior to each dose of study treatment&#xD;
&#xD;
          -  Warfarin used or required within 48 hours prior to each dose of study treatment and&#xD;
             the prothrombin time (INR) exceeded the upper limit of normal range&#xD;
&#xD;
          -  Direct thrombin inhibitors or Xa inhibitors&#xD;
&#xD;
          -  Acetylsalicylic acid used or required within 72 hours prior to each dose of study&#xD;
             treatment&#xD;
&#xD;
          -  Clopidogrel bisulfate used or required within 48 hours prior to each dose of study&#xD;
             treatment&#xD;
&#xD;
          -  Anticipated requirement for anti-platelet or anti-coagulant agents excluding&#xD;
             non-aspirin NSAID within 48 hours following study treatment infusion&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No active systemic infection requiring parenteral antibiotic therapy&#xD;
&#xD;
          -  No history of or presence of a CNS disease&#xD;
&#xD;
          -  No history of allergic reactions to compounds of similar chemical or biologic&#xD;
             composition&#xD;
&#xD;
          -  Not HIV positive&#xD;
&#xD;
          -  No women who are pregnant or nursing&#xD;
&#xD;
          -  A negative serum pregnancy test if female&#xD;
&#xD;
          -  Patients, both females and males, with reproductive potential must agree to use&#xD;
             effective contraceptive measures for the duration of the study&#xD;
&#xD;
          -  No history of significant renal, endocrinologic, metabolic, immunologic or hepatic&#xD;
             disease&#xD;
&#xD;
          -  No evidence of psychiatric illness/social situations&#xD;
&#xD;
          -  Other illness that in the opinion of the investigator would exclude the patient from&#xD;
             participating&#xD;
&#xD;
          -  Must provide informed consent and HIPAA authorization and comply with&#xD;
             protocol-specified procedures and follow-up evaluations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Emory University, Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center, James P. Wilmot Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Hematology-Oncology Associates</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>March 9, 2011</study_first_submitted>
  <study_first_submitted_qc>March 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2011</study_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>tissue factor</keyword>
  <keyword>solid tumor</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>breast cancer</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>colon cancer</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>soft-tissue sarcoma</keyword>
  <keyword>metastatic</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>anti-tumor</keyword>
  <keyword>venous thromboembolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

